Development of lipid-based microsuspensions for improved ophthalmic delivery of gentamicin sulphate / Adaeze Linda Onugwu, Chinazom Precious Agbo, Chinekwu Sherridan Nwagwu, Samuel Emeka Uzondu, Adaeze Chidiebere Echezona, John Dike Nwabueze Ogbonna, Franklin Chimaobi Kenechukwu, Chukwuebuka Emmanuel Umeyor, Emmanuel Maduabuchi Uronnachi, Paul Achile Akpa, Mumuni Audu Momoh, Petra Obioma Nnamani, Christel Charlotte Müller-Goymann, Anthony Amaechi Attama
Aim:Anterior eye segment disorders are treated with eye drops and ointments, which have low ocular bioavailability necessitating the need for improved alternatives. Lipid microsuspension of gentamicin sulphate was developed for the treatment of susceptible eye diseases.Materials & methods:Lipid microsuspensions encapsulating gentamicin sulphate were produced by hot homogenization and evaluated.Ex vivopermeation and ocular irritancy tests were also conducted.Results & conclusion:Stable microsuspensions with high entrapment efficiency and satisfactory osmolarities were obtained. Release studies achieved 49–88%in vitrorelease at 12 h with sustained permeability of gentamicin compared with conventional gentamicin eye drop (Evril®). No irritation was observed following Draize’s test. The microsuspensions have great potential as ocular delivery system of gentamicin sulphate. Aim: Materials & methods: Ex vivo Results & conclusion: in vitro ®.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Onugwu, Adaeze Linda [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Gentamicin sulphate |
|---|
| Umfang: |
1 Online-Ressource (13 p) |
|---|
| doi: |
10.4155/tde-2021-0039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011092440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011092440 | ||
| 003 | DE-627 | ||
| 005 | 20230713210628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0039 |2 doi | |
| 035 | |a (DE-627)KFL011092440 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2021-0039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Onugwu, Adaeze Linda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of lipid-based microsuspensions for improved ophthalmic delivery of gentamicin sulphate |c Adaeze Linda Onugwu, Chinazom Precious Agbo, Chinekwu Sherridan Nwagwu, Samuel Emeka Uzondu, Adaeze Chidiebere Echezona, John Dike Nwabueze Ogbonna, Franklin Chimaobi Kenechukwu, Chukwuebuka Emmanuel Umeyor, Emmanuel Maduabuchi Uronnachi, Paul Achile Akpa, Mumuni Audu Momoh, Petra Obioma Nnamani, Christel Charlotte Müller-Goymann, Anthony Amaechi Attama |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (13 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Anterior eye segment disorders are treated with eye drops and ointments, which have low ocular bioavailability necessitating the need for improved alternatives. Lipid microsuspension of gentamicin sulphate was developed for the treatment of susceptible eye diseases.Materials & methods:Lipid microsuspensions encapsulating gentamicin sulphate were produced by hot homogenization and evaluated.Ex vivopermeation and ocular irritancy tests were also conducted.Results & conclusion:Stable microsuspensions with high entrapment efficiency and satisfactory osmolarities were obtained. Release studies achieved 49–88%in vitrorelease at 12 h with sustained permeability of gentamicin compared with conventional gentamicin eye drop (Evril®). No irritation was observed following Draize’s test. The microsuspensions have great potential as ocular delivery system of gentamicin sulphate. Aim: Materials & methods: Ex vivo Results & conclusion: in vitro ® | ||
| 653 | |a gentamicin sulphate | ||
| 653 | |a microsuspension | ||
| 653 | |a osmolarity | ||
| 653 | |a permeation | ||
| 653 | |a solidified reverse micellar solution | ||
| 653 | |a sustained release | ||
| 700 | 1 | |a Agbo, Chinazom Precious |e verfasserin |4 aut | |
| 700 | 1 | |a Nwagwu, Chinekwu Sherridan |e verfasserin |4 aut | |
| 700 | 1 | |a Uzondu, Samuel Emeka |e verfasserin |4 aut | |
| 700 | 1 | |a Echezona, Adaeze Chidiebere |e verfasserin |4 aut | |
| 700 | 1 | |a Nwabueze Ogbonna, John Dike |e verfasserin |4 aut | |
| 700 | 1 | |a Kenechukwu, Franklin Chimaobi |e verfasserin |4 aut | |
| 700 | 1 | |a Umeyor, Chukwuebuka Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Uronnachi, Emmanuel Maduabuchi |e verfasserin |4 aut | |
| 700 | 1 | |a Akpa, Paul Achile |e verfasserin |4 aut | |
| 700 | 1 | |a Momoh, Mumuni Audu |e verfasserin |4 aut | |
| 700 | 1 | |a Nnamani, Petra Obioma |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Goymann, Christel Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Attama, Anthony Amaechi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2021-0039 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||